Inve US ▾
SISINT

Sintx Technologies (SINT) Q2 FY26 earnings call: guidance

Earnings call· Jun 2026 (Q2 FY26)· Health Care· Aug 11, 2026

Source: earnings call transcript

Executive summary

Sintx Technologies Q2 FY26 — Strong Revenue Growth Driven by Product Sales and OEM Orders

Sintx Technologies reported significant revenue growth in Q2 FY26, driven by strong product sales and new OEM contract manufacturing orders, marking a transition towards commercialization. The company is focusing on converting demand into recognized revenue, establishing a disciplined commercial foundation for its foot and ankle wedge system, and prudently managing its cost structure and liquidity. Despite strong top-line growth, the company continues to face liquidity risks and increased net losses, necessitating ongoing efforts to secure additional funding and align expenses with its revenue base.

Highlights

5

  • Total revenue increased 199% year-over-year to $452,000 in Q2 2026.

  • Product revenue surged 347% year-over-year to $447,000 in Q2 2026.

  • Gross profit increased 388% to $278,000, with gross margins improving to approximately 62% from 38% a year ago.

  • Received purchase orders from contract manufacturing customers with an aggregate value exceeding $3.2 million.

  • Recognized initial commercial revenue from the SINTX osteotomy foot and ankle wedge system.

Concerns

5

  • Net loss remained flat at $2.3 million in Q2 2026 compared to the prior year.

  • Net loss for the first six months of 2026 increased to $5.5 million from $4.6 million in the prior year period.

  • Cash and cash equivalents decreased to $3.6 million at June 30, 2026, from $4.1 million at December 31, 2025.

  • Net cash used in operating activities increased to $5.3 million for the first six months of 2026, up from $3.7 million in the prior year period.

  • The current cost structure is high relative to the company's revenue base.

Guidance & targets

CategoryTargetConfidence
Total Revenue
$900,000 to $1.1 million
high materiality
Medium
Total Revenue
$1 million to $1.3 million
high materiality
Medium

Segment performance

SegmentRevenueYoYQoQMargin
Product Revenue
Driven primarily by increased sales in OEM industrial manufacturing business and early commercial sales of the SINTX osteotomy foot and ankle wedge system.
$447,000347%——
Grant and Contract Revenue
Decreased significantly compared to $51,000 in the prior year period.
$5,000-90.2%——

Product announcements

ProductTypeDetails
SINTX osteotomy foot and ankle wedge systemlaunch

Deals & partnerships

Multiple existing contract manufacturing customers Purchase orders for technically demanding components Exceeding $3.2 million Production and shipment activities continuing into 2027

These purchase orders are for components used in applications requiring mechanical strength, thermal stability, wear and corrosion resistance, manufacturing consistency, and quality control.

Chris Lyons (board member) and Southern Metrics Engagement to help coordinate and evaluate inbound strategic opportunities

This engagement is for potential commercial partnerships, licensing relationships, and other business development initiatives. It does not imply any particular transaction is pending or will occur.

Risks & headwinds

Liquidity risk Ongoing

Cash and cash equivalents were $3.6 million at June 30, 2026, compared with $4.1 million at December 31, 2025. Net cash used in operating activities was $5.3 million for H1 2026.

Mitigation:June private placement, remaining ATM capacity ($5.1 million), Armor facility sublease, pricing improvements, divestiture of non-core operations, and seeking additional equity/debt financing.

Uncertainty in revenue recognition for contract manufacturing orders Q3 and Q4 FY26, continuing into 2027

Purchase orders exceeding $3.2 million, but revenue recognition depends on production, shipment, and other customary conditions.

Mitigation:Aligning production schedules, managing working capital, protecting quality and delivery, evaluating capacity and process efficiency.

High cost structure relative to revenue base Near-term

General and administrative expense increased 64% to $2.3 million in Q2 2026.

Mitigation:Management is evaluating staffing, outside services, facilities, project priorities, working capital, and other spending to align with value creation milestones.

Working capital pressure from contract manufacturing orders Ongoing

Inventory was $2.3 million at June 30, 2026, compared with $1 million at year end, reflecting inventory purchases and production activity.

Mitigation:Balancing supplier support and customer delivery requirements with responsible cash management; disciplined growth that avoids excessive working capital pressure.

Surgeon adoption and channel development for foot and ankle wedge system Ongoing

Initial commercial revenue recognized, but timing and amount of future revenue depend on surgeon adoption, channel development, product availability, and other market factors.

Mitigation:Establishing a disciplined commercial foundation, surgeon education, case support, evaluating capital-efficient routes to market (direct-to-surgeon, distributors, strategic relationships).

What to watch in Q3 FY26

Contract manufacturing revenue conversion

Q3 FY26 and Q4 FY26
Current Purchase orders exceeding $3.2 million received, production started.
Target Recognized revenue within Q3 and Q4 FY26 guidance range ($0.9M-$1.1M for Q3, $1.0M-$1.3M for Q4).

Why it matters

Successful conversion of orders to revenue is crucial for demonstrating execution and achieving financial targets, validating the commercial foundation.

Based on our current production schedules, customer requirements, and expectations regarding the timing of shipments, we currently expect total revenue to be approximately $900,000 to $1.1 million in the third quarter and approximately $1 million to $1.3 million in the fourth quarter of 2026.

Find out whether SINT delivers this. Inve re-checks your case every morning.

2 min read 6 chapters

Detailed narrative

Transition to Commercial Focus

SINTX Technologies is actively transitioning from a development-focused company to a commercially oriented biomaterials and medical technology platform. This shift is evidenced by the significant increase in product revenue and the initial commercialization of its proprietary medical devices. The company emphasizes converting demand into recognized revenue, establishing repeatable commercialization efforts, and aligning its cost structure with business scale.

Contract Manufacturing Business Performance

The OEM industrial manufacturing business served as a primary driver of product revenue growth in Q2 2026, reflecting improved customer demand and pricing. SINTX views this segment as a crucial commercial foundation, providing near-term revenue, customer validation, and manufacturing utilization. The company announced receiving purchase orders exceeding $3.2 million, with production and shipment activities expected to continue into 2027, highlighting the significant value relative to current revenue.

Proprietary Medical Portfolio: Foot and Ankle Wedge System

The SINTX foot and ankle osteotomy wedge system, which received FDA 510(k) clearance in late 2025, is the company's lead commercial product. Initial commercial revenue was recognized in Q2 2026 following its first clinical use in March 2026. The company is focused on building adoption and increasing commercial activity through surgeon education, channel development, and capital-efficient market access models, rather than pursuing growth at any cost.

Silicon Nitride Platform Potential

SINTX's silicon nitride platform offers a combination of valuable properties for musculoskeletal applications, including biocompatibility, bone affinity, and imaging compatibility. Beyond the wedge system, the platform has potential applications across orthopedics, spine, dental, and wound care, utilizing various formats like monolithic implants, powders, and coatings. The company is prioritizing programs based on time to revenue, capital requirements, and strategic value.

Strategic Focus and Partnerships

The company's strategy includes converting contract manufacturing demand, building a credible commercial path for the foot and ankle wedge system, and advancing OEM licensing and strategic discussions. SINTX is exploring partnerships to gain market access, development funding, and manufacturing volume, and has engaged a board member's company to evaluate inbound strategic opportunities. This approach aims to leverage external capabilities rather than building every commercial function internally.

Cost Structure and Liquidity Management

While sales and marketing expenses increased due to product launch activities, research and development expenses declined primarily due to overhead reallocation to general and administrative expenses. Management acknowledges that the current cost structure is high relative to its revenue base and is actively evaluating staffing, outside services, facilities, and project priorities to align spending. The company continues to seek additional funding through equity and/or debt financing to address underlying liquidity risks.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.